Antipsychotic drugs: challenges and future directions.
作者信息
Howes Oliver H, Kaar Stephen J
机构信息
Institute of Psychiatry, Psychology & Neuroscience, King's College London, London, UK.
Medical Research Council London Institute of Medical Sciences, London, UK.
出版信息
World Psychiatry. 2018 Jun;17(2):170-171. doi: 10.1002/wps.20522.
Abstract
摘要
相似文献
1
Antipsychotic drugs: challenges and future directions.抗精神病药物：挑战与未来方向。
World Psychiatry. 2018 Jun;17(2):170-171. doi: 10.1002/wps.20522.
2
Intranasal delivery of antipsychotic drugs.抗精神病药物的鼻内给药。
Schizophr Res. 2017 Jun;184:2-13. doi: 10.1016/j.schres.2016.11.027. Epub 2016 Nov 29.
3
[Current state and vision of the development of new antipsychotic drugs].[新型抗精神病药物的发展现状与展望]
Nihon Rinsho. 2013 Apr;71(4):730-6.
4
[Receptor occupancy and antipsychotic drug action measured by PET and SPECT].[通过正电子发射断层扫描（PET）和单光子发射计算机断层扫描（SPECT）测量的受体占有率与抗精神病药物作用]
Seishin Shinkeigaku Zasshi. 2001;103(4):329-40.
5
Caring for women with epilepsy: Qualitative exploration of key challenges and future directions in a resource poor healthcare system.关爱癫痫女性：资源匮乏医疗体系下的关键挑战和未来方向的定性探索。
Epilepsy Behav. 2022 Apr;129:108622. doi: 10.1016/j.yebeh.2022.108622. Epub 2022 Feb 28.
6
DNA methylation and antipsychotic treatment mechanisms in schizophrenia: Progress and future directions.精神分裂症中的 DNA 甲基化和抗精神病药物治疗机制：进展与未来方向。
Prog Neuropsychopharmacol Biol Psychiatry. 2018 Feb 2;81:38-49. doi: 10.1016/j.pnpbp.2017.10.004. Epub 2017 Oct 7.
7
Personalizing antipsychotic treatment: evidence and thoughts on individualized tailoring of antipsychotic dosage in the treatment of psychotic disorders.个性化抗精神病药物治疗：关于在精神障碍治疗中对抗精神病药物剂量进行个体化调整的证据与思考
Ther Adv Psychopharmacol. 2019 Apr 8;9:2045125319836566. doi: 10.1177/2045125319836566. eCollection 2019.
8
Antipsychotic drugs and sudden cardiac death: A literature review of the challenges in the prediction, management, and future steps.抗精神病药物与心源性猝死：预测、管理及未来措施相关挑战的文献综述。
Psychiatry Res. 2019 Nov;281:112598. doi: 10.1016/j.psychres.2019.112598. Epub 2019 Oct 3.
9
Effects of antipsychotic drugs on cytokine networks.抗精神病药物对细胞因子网络的影响。
J Psychiatr Res. 2000 Nov-Dec;34(6):369-82. doi: 10.1016/s0022-3956(00)00032-7.
10
Maintenance treatment with antipsychotic drugs for schizophrenia.使用抗精神病药物对精神分裂症进行维持治疗。
Cochrane Database Syst Rev. 2012 May 16(5):CD008016. doi: 10.1002/14651858.CD008016.pub2.
引用本文的文献
1
Antipsychotic Maintenance Treatment for Patients With Schizophrenia: The Need for Placebo-Controlled Trials and The Risk of Paradigm Shifts.精神分裂症患者的抗精神病药物维持治疗：安慰剂对照试验的必要性及范式转变的风险
Schizophr Bull Open. 2022 Oct 18;3(1):sgac058. doi: 10.1093/schizbullopen/sgac058. eCollection 2022 Jan.
2
Schizophrenia: from neurochemistry to circuits, symptoms and treatments.精神分裂症：从神经化学到回路、症状和治疗。
Nat Rev Neurol. 2024 Jan;20(1):22-35. doi: 10.1038/s41582-023-00904-0. Epub 2023 Dec 18.
3
The effects of AUT00206, a novel Kv3.1/3.2 potassium channel modulator, on task-based reward system activation: a test of mechanism in schizophrenia.AUT00206，一种新型的 Kv3.1/3.2 钾通道调节剂，对基于任务的奖励系统激活的影响：精神分裂症机制的检验。
Psychopharmacology (Berl). 2022 Oct;239(10):3313-3323. doi: 10.1007/s00213-022-06216-3. Epub 2022 Sep 12.
4
New Paradigms of Old Psychedelics in Schizophrenia.精神分裂症中传统迷幻药物的新范式
Pharmaceuticals (Basel). 2022 May 23;15(5):640. doi: 10.3390/ph15050640.
5
Advances and Challenges in Intranasal Delivery of Antipsychotic Agents Targeting the Central Nervous System.靶向中枢神经系统的抗精神病药物鼻内给药的进展与挑战
Front Pharmacol. 2022 Mar 24;13:865590. doi: 10.3389/fphar.2022.865590. eCollection 2022.
6
Animal-Assisted Therapy in Middle-Aged and Older Patients With Schizophrenia: A Randomized Controlled Trial.中年及老年精神分裂症患者的动物辅助治疗：一项随机对照试验。
Front Psychiatry. 2021 Aug 3;12:713623. doi: 10.3389/fpsyt.2021.713623. eCollection 2021.
7
Towards in vivo imaging of functionally active 5-HT receptors in schizophrenia: concepts and challenges.迈向精神分裂症中功能活性5-羟色胺受体的体内成像：概念与挑战。
Transl Psychiatry. 2021 Jan 7;11(1):22. doi: 10.1038/s41398-020-01119-3.
8
Emerging therapeutic targets for schizophrenia: a framework for novel treatment strategies for psychosis.精神分裂症的新兴治疗靶点：精神病新型治疗策略的框架。
Expert Opin Ther Targets. 2021 Jan;25(1):15-26. doi: 10.1080/14728222.2021.1849144. Epub 2020 Nov 26.
9
The role of shared decision-making in improving adherence to pharmacological treatments in patients with schizophrenia: a clinical review.共同决策在提高精神分裂症患者药物治疗依从性中的作用：一项临床综述
Ann Gen Psychiatry. 2020 Aug 5;19:43. doi: 10.1186/s12991-020-00293-4. eCollection 2020.
10
The effect of NMDA-R antagonist, MK-801, on neuronal mismatch along the rat auditory thalamocortical pathway.NMDA 受体拮抗剂 MK-801 对大鼠听丘脑皮质通路神经元失配对的影响。
Sci Rep. 2020 Jul 24;10(1):12391. doi: 10.1038/s41598-020-68837-y.
本文引用的文献
1
What is the risk-benefit ratio of long-term antipsychotic treatment in people with schizophrenia?精神分裂症患者长期使用抗精神病药物治疗的风险效益比是多少？
World Psychiatry. 2018 Jun;17(2):149-160. doi: 10.1002/wps.20516.
2
Heterogeneity and Homogeneity of Regional Brain Structure in Schizophrenia: A Meta-analysis.精神分裂症患者脑区结构的异质性与同质性：一项荟萃分析。
JAMA Psychiatry. 2017 Nov 1;74(11):1104-1111. doi: 10.1001/jamapsychiatry.2017.2663.
3
Sixty Years of Placebo-Controlled Antipsychotic Drug Trials in Acute Schizophrenia: Systematic Review, Bayesian Meta-Analysis, and Meta-Regression of Efficacy Predictors.60 年来抗精神病药物治疗急性精神分裂症的安慰剂对照试验：系统评价、贝叶斯荟萃分析和疗效预测因素的荟萃回归。
Am J Psychiatry. 2017 Oct 1;174(10):927-942. doi: 10.1176/appi.ajp.2017.16121358. Epub 2017 May 25.
4
Treatment-Resistant Schizophrenia: Treatment Response and Resistance in Psychosis (TRRIP) Working Group Consensus Guidelines on Diagnosis and Terminology.难治性精神分裂症：精神病治疗反应与抵抗（TRRIP）工作组关于诊断和术语的共识指南
Am J Psychiatry. 2017 Mar 1;174(3):216-229. doi: 10.1176/appi.ajp.2016.16050503. Epub 2016 Dec 6.
5
Two distinct patterns of treatment resistance: clinical predictors of treatment resistance in first-episode schizophrenia spectrum psychoses.两种不同的治疗抵抗模式：首发精神分裂症谱系精神病治疗抵抗的临床预测因素。
Psychol Med. 2016 Nov;46(15):3231-3240. doi: 10.1017/S0033291716002014. Epub 2016 Sep 8.
6
Secondary negative symptoms - A review of mechanisms, assessment and treatment.继发性阴性症状——机制、评估与治疗综述
Schizophr Res. 2017 Aug;186:29-38. doi: 10.1016/j.schres.2016.05.003. Epub 2016 May 24.
7
Impact of cognitive and social cognitive impairment on functional outcomes in patients with schizophrenia.认知和社会认知障碍对精神分裂症患者功能结局的影响。
J Clin Psychiatry. 2016 Feb;77 Suppl 2:8-11. doi: 10.4088/JCP.14074su1c.02.
8
Novel Findings from CNVs Implicate Inhibitory and Excitatory Signaling Complexes in Schizophrenia.拷贝数变异的新发现表明精神分裂症中存在抑制性和兴奋性信号复合物。
Neuron. 2015 Jun 3;86(5):1203-14. doi: 10.1016/j.neuron.2015.04.022.
9
Glutamate and dopamine in schizophrenia: an update for the 21st century.精神分裂症中的谷氨酸和多巴胺：21世纪的最新进展
J Psychopharmacol. 2015 Feb;29(2):97-115. doi: 10.1177/0269881114563634. Epub 2015 Jan 13.
10
Schizophrenia: an integrated sociodevelopmental-cognitive model.精神分裂症：一种综合的社会发展认知模型。
Lancet. 2014 May 10;383(9929):1677-1687. doi: 10.1016/S0140-6736(13)62036-X. Epub 2013 Dec 6.
Zotero 插件